Advicenne announced that it has received authorization from the Belgian health authority (FAMHP) to begin a pivotal Phase II/III CORAL clinical trial in cystinuria with its drug candidate, ADV7103. The French pharmaceutical company also assesses its financial visibility at the close of 2018. Previously authorized for studies in patients suffering from dRTA, the recently approved pivotal Phase II/III clinical trial has been designed to evaluate the efficacy, safety, tolerance and compliance of ADV7103 in patients living with cystinuria. It does so in anticipation of the drug candidate’s approval for this second indication in Europe, which is expected to double the size of its market population.